2027 Medicare Advantage Payment Rates: Key Insights from CMS Update
This week, the Centers for Medicare and Medicaid Services (CMS) announced the Calendar Year 2027 Medicare Advantage (MA) and Part D Rates. The update reveals an anticipated net impact change of 2.48% in payment rates, translating into an additional $13 billion for MA plans. This significant increase surpasses the 0.09% rise projected in January, reflecting a trend towards stabilization while enforcing targeted payment integrity constraints.
A critical adjustment contributing to the changes in final rates is found in the "risk model and normalization" category. The anticipated rate improved from a projected -3.32% to -1.12%, alleviating what could have been more severe cuts in MA payments. Furthermore, the effective growth rate slightly increased from 4.97% to 5.33%. In comparison, adjustments for "sources of diagnoses" remained at -1.53%, with Star Ratings and MA risk score trends holding consistent with previous evaluations.
In a notable policy decision, CMS opted not to adopt the updated 2027 CMS Hierarchical Condition Categories (CMS-HCC) risk adjustment model. Instead, they will retain the 2024 model for CY 2027. This move aims to ensure stability and give plans time to adapt to changes, thus sustaining MA's significant role in serving over 35 million individuals within the Medicare framework.
The current rate announcement efforts to maintain MA plan participation and promote stable bidding for the upcoming year. Despite the overall payment rise, CMS's strategy underscores the necessity to control inappropriate payment growth. Particularly, by excluding diagnoses from unlinked chart reviews, with a few exceptions, CMS projects substantial Medicare savings of $6.84 billion. Incremental changes related to rebasing and repricing suggest minimal adjustments, while excluding certain audio-only services bears negligible impact.
The strategy exemplifies CMS's dedication to balancing increased initial payments with strict program integrity oversight. As MA enrollment continues to rise, future policy refinements will likely focus on risk adjustment challenges and documentation of payment justifications. Viewing the payment enhancements as part of a strategic measure, the aim is to support stability and competition in the MA market, rather than signaling a long-term shift towards more lenient reimbursement policies.